US Psoriasis Treatment Market for Biologics & Biosimilars to Reach USD 12.9 Bn by 2021, States MP Advisors in Report Available at MarketPublishers.com

03 Nov 2017 • by Natalie Aster

LONDON – The US psoriasis treatment market for biologics and biosimilars stood at USD 6.6 billion in 2016 is poised to almost double in the offing to reach USD 12.9 billion by 2021, stimulated by higher levels of safety and efficacy of the new-generation biologics (biobetters, biosuperiors).

Fuelled by enhanced efficacy, the first group of anti TNF drugs dominated by Enbrel, Humira and Remicade made strong inroads into the psoriasis market. Although, the emergence of the interleukin-17 (IL-17) inhibitor class driven by Novartis’ Cosentyx and Eli Lilly’s Talz have set a novel benchmark for efficacy in the treatment of moderate-to-severe psoriasis with potential for safety enhancement versus the anti TNF treatments due to their greater specificity in immunosuppression. The TNF drug classes are expected to lose share to the newer brands with improved clinical profiles in psoriasis.

The market growth is being driven by a hike in demand from novel therapies in patients with moderate-to-severe psoriasis, which overshadows reduced pricing of branded TNF-α inhibitors as well as recent biosimilar launches. The psoriasis treatment sector is seeing a growing competitive pressure from a slew of biosimilar launches like Janssen’s Remicade, and Amgen’s Enbrel with the impact of the bottlenecks anticipated to be more evident in the foreseeable future.

Topical report “The Future of the U.S. Biologics and Biosimilars Treatment Market for Psoriasis” developed by MP Advisors provides an all-round assessment of the psoriasis market on a national level.

It gives information on the disease background, types of psoriasis, pathophysiology, etiology, risk factors and co-morbidities, treatment modalities and guidelines. The study gives an overview of the psoriasis treatment market for biologics, provides revenue analysis for biologics in the USA, key marketed products for psoriasis treatment, identifies the major growth drivers and restraints for biologics, examines the competitive scenario covering approved and pipeline products. The report examines the psoriasis market for biosimilars, covering approved biosimilars, analysis of the pipeline, deals and partnerships in the marketplace, market propellers and hindrances, and the competitive landscape.

More comprehensive reports by the publisher can be found at MP Advisors page.

CONTACTS

The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com
MarketPublishers.com